Neximmune reports first quarter 2023 financial results and provides business updates

Gaithersburg, md., may 15, 2023 (globe newswire) -- neximmune, inc. (nasdaq: nexi), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells in oncology, autoimmune and infectious diseases, today reported financial results for the first quarter 2023.
NEXI Ratings Summary
NEXI Quant Ranking